[{"orgOrder":0,"company":"Applied BioMath","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"CLN-049","moa":"FLT3","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Applied BioMath \/ Cullinan Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied BioMath \/ Cullinan Therapeutics"},{"orgOrder":0,"company":"Applied BioMath","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied BioMath \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied BioMath \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Applied BioMath","sponsor":"OncoMyx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied BioMath \/ OncoMyx Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied BioMath \/ OncoMyx Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Applied BioMath

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vietnam Medi Pharm
                          Not Confirmed
                          Vietnam Medi Pharm
                          Not Confirmed

                          Details : In this collaboration, Applied BioMath is developing a model of SpringWorks' investigational oral selective small molecule gamma secretase inhibitor, nirogacestat (PF-03084014), in combination with an agent that targets B-cell maturation antigen for mult...

                          Product Name : PF-03084014

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 11, 2022

                          Lead Product(s) : Nirogacestat Hydrobromide,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : SpringWorks Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Vietnam Medi Pharm
                          Not Confirmed
                          Vietnam Medi Pharm
                          Not Confirmed

                          Details : Applied BioMath will develop a systems pharmacology model for CLN-049, a novel FLT3XCD3 bispecific antibody for Acute Myeloid Leukemia, being developed by Cullinan Florentine, a Cullinan Oncology company.

                          Product Name : CLN-049

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          September 29, 2020

                          Lead Product(s) : CLN-049

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Cullinan Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Vietnam Medi Pharm
                          Not Confirmed
                          Vietnam Medi Pharm
                          Not Confirmed

                          Details : Applied BioMath will develop a systems pharmacology model to mechanistically evaluate the pharmacokinetics and pharmacodynamics of OncoMyx's MYXV platform and therapeutic programs.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 14, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : OncoMyx Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank